Epigenetics, Nutrition, Disease and Drug Development

Author(s): Kenneth Lundstrom*

Journal Name: Current Drug Discovery Technologies

Volume 16 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Epigenetic mechanisms comprising of DNA methylation, histone modifications and gene silencing by RNA interference have been strongly linked to the development and progression of various diseases. These findings have triggered research on epigenetic functions and signal pathways as targets for novel drug discovery. Dietary intake has also presented significant influence on human health and disease development and nutritional modifications have proven important in prevention, but also the treatment of disease. Moreover, a strong link between nutrition and epigenetic changes has been established. Therefore, in attempts to develop novel safer and more efficacious drugs, both nutritional requirements and epigenetic mechanisms need to be addressed.

Keywords: DNA methylation, histone modification, RNA interference, micro-RNA, nutrition, drug discovery.

Wishart DS. Bioinformatics in drug development and assessment. Drug Metab Rev 2005; 37(2): 279-310.
Barak Y, Fridman D. Impact of Mediterranean diet on cancer: focused literature review. Cancer Genomics Proteomics 2017; 14(6): 403-8.
Cui J, Zhou B, Ross SA, Zempleni J. Nutrition, Micro-RNA and Human Health. Adv Nutr 2017; 8(1): 105-12.
Ornish D. Changes in prostate gene expression in men undergoing an intensive nutrition and life style intervention. Proc Natl Acad Sci USA 2008; 105(24): 8369-74.
Su LJ, Mahabir S, Ellison GL, McGuinn LA, Reid BC. Epigenetic contributions to the relationship between cancer and dietary intake of nutrients, bioactive food components and environmental toxicants. Front Genet 2012; 2: 91.
Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 2013; 33(8): 2989-96.
Harrison IF, Dexter DT. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson’s disease? Pharmacol Ther 2014; 140(1): 34-52.
Lundstrom K. MicroRNA in disease and gene therapy. Curr Drug Discov Technol 2011; 8(2): 76-86.
Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66: 1191-308.
World Cancer Research Fund. American Institute of Cancer Research, Diet, Nutrition and Prevention of Human Cancer: A Global Perspective, World Cancer Research Fund. Washington: American Institute of Cancer Research 2007.
Ouédraogo M, Charles C, Ouédraogo M, Guissou IP, Stévigny C, Duez P. An overview of cancer chemopreventive potential and safety of proanthocyanidins. Nutr Cancer 2011; 63(8): 1163-73.
Campbell TC. Cancer prevention and treatment by wholistic nutrition. J Nat Sci 2017; 3(10)e448
Lundstrom K. Nutrition and cancer. EC Nutr 2017; 8(6): 207-23.
Lampe JW. Interindividual differences in response to plant-based diets: implications for cancer risk. Am J Clin Nutr 2009; 89: 1553S-7S.
Milner JA. Nutrition and cancer: essential elements for a roadmap. Cancer Lett 2008; 269: 189-98.
Rienks J, Barbaresko J, Nöthlings U. Association of isoflavone biomarkers with risk of chronic disease and mortality: a systematic review and meta-analysis of observational studies. Nutr Rev 2017; 75(8): 616-41.
Yang L, Ling W, Du Z, et al. Effects of anthocyanins on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2017; 8(5): 684-93.
Souza PAL, Marcadenti A, Portal VL. Effects of olive oil phenolic compounds on inflammation in the prevention and treatment of coronary artery disease. Nutrients 2017; 9(10): E1087.
Superko HR, Zhao XQ, Hodis HN, Guyton JR. Niacin and heart disease prevention: Engraving its tombstone is a mistake. J Clin Lipidol 2017; 11(6): 1309-17.
Patel H, Chandra S, Alexander S, Soble J, Williams KA Sr. Plant-based nutrition: An essential component of cardiovascular disease prevention and management. Curr Cardiol Rep 2017; 19(10): 104.
Martin MA, Goya L, Ramos S. Protective effects of tea, red wine and cocoa in diabetes: Evidences from human studies. Food Chem Toxicol 2017; 109(Pt1): 302-14.
Kou X, Chen N. Resveratrol as a natural autophagy regulator for prevention and treatment of Alzheimer’s disease. Nutrients 2017; 9(9): E927.
Munoz-Fernandez SS, Ivanauskas T, Lima Ribeiro SM. Nutritional strategies in the management of Alzheimer’s disease: Systematic review with network meta-analysis. J Am Med Dir Assoc 2017; 18(10): 897.
Sur S, Panda CK. Molecular aspects of cancer chemopreventive and therapeutic efficacies of tea and tea polyphenols. Nutrition 2017; 43-44: 8-15.
Puccinelli MT, Stan SD. Dietary active diallyl trisulfide in cancer prevention and therapy. Int J Mol Sci 2017; 18: 8-E1645.
Hashemian M, Murphy G, Etemadi A, Daawsey SM, Liao LM, Abnet CC. Nut and peanut butter consumption and the risk of esophageal and gastric cancer subtypes. Am J Clin Nutr 2017; 106(3): 858-64.
Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
Baccarelli A, Bollati V. Epigenetics and environmental chemicals. Curr Opin Pediatr 2009; 21: 243-51.
Bollati V, Baccarelli A. Environmental epigenetics. Heredity 2010; 105: 105-12.
Banno X, Yanokura M, Iida M, Masuda K, Aoki D. Carcinogenic of endometrial cancer: involvement of genetics and epigenetics. J Obstet Gynealog Res 2014; 40: 1957-67.
Wang F, Yang Y, Fu Z, et al. Differential DNA methylation status between breast carcinomarous and normal tissues. Biomed Pharmacother 2014; 68: 699-707.
Reyngold M, Turcan S, Giri D, et al. Remodeling of the methylation landscape in breast cancer metastasis. PLoS One 2014; 9e103896
Brocks D, Assenov Y, Minner S, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep 2014; 8: 798-806.
Benard A, Zeestraten EC, Goossens-Beumer IJ, et al. DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence. Apoptosis 2014; 19: 1581-93.
Shimazu T, Asada K, Charvat H, et al. Association of gastric cancer risk factors with DNA methylation levels in gastric mucosa of healthy Japanese: a cross-sectional study. Carcinogenesis 2015; 36: 1291-8.
Horsburgh S, Robson-Ansley P, Adams R, Smith C. Exercise and inflammation-related epigenetic modifications: focus on DNA methylation. Exerc Immunol Rev 2015; 21: 26-41.
White AJ, Sandler DP, Bolick SC, Xu Z, Taylor JA, DeRoo LA. Recreational and household physical activity at different time points and DNA global methylation. Eur J Cancer 2013; 49: 2199-206.
Zhang FF, Santella RM, Wolff M, Kappil MA, Markowitz SB, Morabia A. White blood cell global methylation and IL-6 promoter methylation in association with diet and lifestyle risk factors in a cancer-free population. Epigenetics 2012; 7: 606-14.
Luttropp K, Nordfors L, Ekstrom TJ, Lind L. Physical activity is associated with decreased global DNA methylation in Swedish older individuals. Scand J Clin Lab Invest 2013; 73: 183-4.
Kaimori JY, Maehara K, Hayashi-Takanaka Y, et al. Histone H4 lysine 20 acetylation is associated with gene expression in human cells. Sci Rep 2016; 6: 24318.
Ahrens TD, Timme S, Hoeppner J, et al. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics 2015; 10: 431-45.
Duenas-Gonzalez A, Coronel J, Cetina L, Gonzale-Fierro A, Chavez-Blanco A, Taja-Chayeb L. Hydralazine-valproate: A repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol 2014; 10: 1433-44.
Wang LT, Liuo JP, Li YH, Liu YM, Pan SL, Tenq CM. A novel class 1 HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin. Oncotarget 2014; 5: 5651-62.
Apuri S, Sokol L. An overview of investigational histone deacetylase inhibitors (HDACIs) for the treatment of Non-Hodgkin’s lymphoma. Expert Opin Investig Drugs 2016; 25(6): 687-96.
Yi X, Jiang X, Li X, Jiang DS. Histone lysine methylation and congenital heart disease: From bench to bedside (Review). Int J Mol Med 2017; 40(4): 953-64.
Marsh DJ, Shah JS, Cole AJ. Histones and their modifications in ovarian cancer – drivers of disease and therapeutic targets. Front Oncol 2014; 4: 144.
Chen X, Xie D, Zhao Q, You ZH. MicroRNAs and complex diseases: from experimental results to computational models. Brief Bioinform 2017. [Epub ahead of print].
Grossi I, Salvi A, Abeni E, Marchina E, De Petro G. Biological function of miR-193a-3p in health and disease. Int J Genomics 2017; 20175913195 Epub ahead of print
Janaka Ramaiah M, Naushad SM, Lavanaya PON, Gayatri A, Vaishnave S, Pal-Bhadra M. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple–negative breast cancer. Gene 2017; S0378-1119(17): 30831-4.
Motti ML, D’Angelo S, Meccariello R. MicroRNA, cancer and diet: facts and new exciting perspectives. Curr Mol Pharmacol 2017. [Epub ahead of print].
Drury RE, O’Connor D, Pollard AJ. The clinical application of miRNAs in infectious disease. Front Immunol 2017; 8: 1182.
Péter S, Navis G, de Borst MH, et al. Public health relevance and drug-nutrition interactions. Eur J Nutr 2017. [Epub ahead of print].
Lundstrom K. Past, present and future of nutrigenomics and its influence on drug development. Curr Drug Discov Technol 2013; 10: 35-46.
Dongiovanni P, Valenti L. A nutrigenomic approach to non-alcoholic fatty liver disease. Int J Mol Sci 2017; 18: 1534.
Dajani A, Abu Hammour A. Treatment of nonalcoholic fatty liver disease. Where do we stand? An overview. Saudi J Gastroenterol 2016; 22(2): 91-105.
García Díaz E, Martín Folgueras T. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. Nutr Hosp 2011; 26: 451-7.
Hsiao TJ, Wu LS, Huang SY, Lin E. A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity. Clin Pharmacol 2010; 2: 105-10.
Baylin SB, Jones PA. The epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 2016; 8(9): a019505
Shao Z, Xu P, Xu W, et al. Discovery of novel methyltransferase 3A inhibitors via structure-based virtual screening and biological assays. Bioorg Med Chem Lett 2016; 27(2): 342-6.
Cura V, Marechal N, Troffer-Charlier N, et al. Structural studies of protein arginine methyltransferase 2 reveal its interactions with potential substrates and inhibitors. FEBS J 2017; 284(1): 77-96.
Okochi-Takada E, Hattori N, Ito A, et al. Establishment of a high-throughput detection system for DNA methylating agents. Epigenetics 2016. [Epub ahead of print].
Agrawal K, Das V, Otmar M, Krečmerová M, Džubák P, Hajdúch M. Cell-based demethylation detection system for screening of epigenetic drugs in 2D, 3D and xenograft models. Cytometry A 2017; 91(2): 133-43.
Naveja JJ, Medina-Franco JL. Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery. Expert Opin Drug Discov 2015; 10(10): 1069-70.
Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular disease. Chonnam Med J 2016; 52: 1-11.
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat treatment for advanced cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-52.
Wu YS, Quan Y, Zhang DX, Liu DW, Zhang XZ. Synergistic inhibition of breast cancer cell growth by an epigenome-targeting drug and a tyrosine kinase inhibitor. Biol Pharm Bull 2017; 40(10): 1747-53.
Subramanian K, Raunivar N, Lavalleé-Adam M, Yates JR 3rd, Balch WE. Quantitative analysis of the proteome response to the histone deacetylase inhibitor (HDACi) vorinostat in Niemann-Pick type C1 disease. Mol Cell Proteomics 2017; Aug 31. pii: mcp.M116.064949 [Epub ahead of print].
Tiwari A, Mukheriee B, Dixit M. MicroRNA key to angiogenesis regulation: miRNA biology and therapy. Curr Cancer Drug Targets 2017. [Epub ahead of print].
Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J 2017. [Epub ahead of print].
van der Ree H, Stelma F, Willemse SB, et al. Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Antiviral Res 2017; 146: 139-45.
Lanford RE, Hildebrandt-Eriksen ES, Petri A. Therapeutic silencing of MicroRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962): 198-201.
Titze-ed-Almeida R. David C, Titze-de-Almeida SS. The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res 2017; 34(7): 1339-63.
Scudellari M. The science myths that will not die. Nature 2015; 528(7582): 322-5.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [386 - 391]
Pages: 6
DOI: 10.2174/1570163815666180419154954
Price: $65

Article Metrics

PDF: 34